Placebo PH20 SC

OTHER12 trials

Sponsors

Argenx, argenx

Conditions

Autoimmune Encephalitis (AE)Graves DiseaseGraves' DiseaseHealthy VolunteersMyasthenia Gravis, OcularOcular Myasthenia GravisPrimary Immune ThrombocytopeniaPrimary Sjogrens Disease

Phase 1

SAD and MAD Study With IV and SC Doses of ARGX-117

CompletedNCT04532125

argenxHealthy Volunteers

Start: 2020-08-03End: 2022-08-26Updated: 2022-09-21

Phase 2

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

RecruitingNCT06655155

argenxSystemic Sclerosis (SSc)

Start: 2024-11-11End: 2027-09-01Target: 81Updated: 2026-09-17

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

RecruitingNCT07583641

argenxAutoimmune Encephalitis (AE)

Start: 2026-08-15End: 2029-05-12Target: 170Updated: 2026-08-24

A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

Not yet recruitingNCT07760818

argenxPrimary Sjögren's Syndrome Painful Sensory Neuropathies, Sjogrens Disease

Start: 2026-08-14End: 2029-07-28Target: 75Updated: 2026-08-12

Phase 3

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

CompletedNCT04687072

argenxPrimary Immune Thrombocytopenia

Start: 2020-12-16End: 2023-10-09Updated: 2024-10-31

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

TerminatedNCT06307613

argenxThyroid Eye Disease

Start: 2024-03-27End: 2026-02-12Updated: 2026-03-16

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

TerminatedNCT06307626

argenxThyroid Eye Disease

Start: 2024-03-28End: 2026-02-12Updated: 2026-03-16

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

Active, not recruitingNCT06558279

argenxMyasthenia Gravis, Ocular

Start: 2024-09-18End: 2027-12-01Updated: 2026-07-02

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Active, not recruitingNCT06684847

argenxPrimary Sjogrens Disease

Start: 2025-01-15End: 2028-07-01Updated: 2026-04-16

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis

Active, not recruitingCTIS2024-514133-38-00

ArgenxOcular Myasthenia Gravis

Start: 2025-03-19Target: 169Updated: 2025-12-05

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

RecruitingNCT07570316

argenxGraves Disease, Graves' Disease

Start: 2026-06-10End: 2030-05-01Target: 230Updated: 2026-09-17

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

RecruitingNCT07596849

argenxGraves Disease

Start: 2026-06-10End: 2030-05-01Target: 230Updated: 2026-09-17

Related Papers

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

2026-04-06

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart

Nature Communications2025-08-162 citations

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Blood2021-11-051 citations